Sabby Management’s SELLAS Life Sciences SLS Stock Holding History

Sabby Management’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1	Closed	-$164K	–	308
2016 Q4	$164K	Buy	+1	New	+$5.82K	0.01%	253

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $36.1B AUM 19.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Sabby Management's SLS Position: Q3 2019 in Review

Sabby Management sold out of SELLAS Life Sciences (SLS) in Q3 2019, closing a stake of 78,520 shares — an estimated $442K sold.

Sabby Management first reported a position in SLS in Q4 2016 and held it in 8 quarters. The position peaked at $1.54M in Q2 2017. 18 funds tracked by Wall St. Rank hold SLS as of Q3 2019.

Sabby Management reported no remaining SELLAS Life Sciences position as of Q3 2019 after selling out during the quarter.
Sabby Management sold 78,520 SELLAS Life Sciences shares in Q3 2019, an estimated $442K.
Sabby Management first reported a position in SELLAS Life Sciences in Q4 2016 and held it in 8 quarters.
Sabby Management's SELLAS Life Sciences position peaked at $1.54M in Q2 2017.
18 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2019.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.